C-HCT0SAP depletion, amyloid immunotherapy, CRP inhibition
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Inhibit C-reactive protein as a therapeutic strategy for CRP-associated pathology.
Small-molecule CRP inhibition using listed compounds including bis(phosphocholine)-octane and BPC8.
Program is listed among Pentraxin Therapeutics R&D areas and pipeline agents.
Site-listed publication Nature 2006 is associated with this program area.
Use SAP depletion to improve or enable DNA vaccination approaches.
Research program applying SAP depletion biology to DNA vaccination.
Program is listed as one of Pentraxin Therapeutics' R&D focus areas.
Site analysis identifies SAP depletion for DNA vaccination as an R&D program, but no specific results are supplied.
Target serum amyloid P component in Alzheimer's disease as a disease-modifying therapeutic approach.
SAP depletion or SAP-targeted intervention using listed agents including CPHPC/miridesap and DESPIAD.
In summer 2018, Apollo Therapeutics invested in the project and planned to progress it in close collaboration with Pepys and the UCL Wolfson Drug Discovery Unit.
Site-listed publications include PNAS 2009, Open Biol 2016, and PLoS ONE 2018 in the SAP/Alzheimer's disease program area.
Treat systemic amyloidosis by targeting serum amyloid P component and promoting clearance of amyloid deposits.
SAP depletion with CPHPC/miridesap and amyloid immunotherapy with dezamizumab anti-SAP antibody.
The Medical Research Council awarded Professor Pepys £3.84 million in 2010 under its Developmental Clinical Studies scheme for this program area.
Site-listed publications include Nature 2002, Br J Haematol 2010, Nature 2010, N Engl J Med 2015, and Sci Transl Med 2018 related to the SAP/amyloidosis program.